Physician profile
Ko Kim
NPI 1811668841
$8,303.68
in general payments reported to CMS, 2019-2025
34 companies · $3,223 in 2025
The $3,223 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.79 · 2022: $244 · 2023: $1,819 · 2024: $3,005 · 2025: $3,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,992 · Travel and Lodging: $1,011 · Education: $42.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,992.30 |
| Travel and Lodging | $1,011.12 |
| Education | $42.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $1,120.37 | 2023-2025 | Ztlido |
| Livanova USA, INC. | $846.65 | 2024 | Vns Therapy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $694.16 | 2022-2025 | Relistor |
| Forte Bio-Pharma LLC | $546.54 | 2022-2025 | Prolate, Nalocet, Tanlor |
| Si-Bone, INC. | $537.24 | 2025 | |
| Axsome Therapeutics, INC. | $495.75 | 2022-2025 | Sunosi |
| Nevro Corp. | $461.53 | 2023-2024 | Senza |
| Valinor Pharma, LLC | $372.65 | 2023-2025 | Movantik |
| Globus Medical, INC. | $367.99 | 2025 | Senza, Vyrsa V1, Omnia |
| Abbvie INC. | $334.73 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $330.54 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $316.44 | 2023-2025 | |
| Neurelis, INC. | $303.67 | 2023-2025 | Valtoco |
| Collegium Pharmaceutical, INC. | $264.53 | 2023-2024 | Belbuca, Xtampza, Nucynta |
| Neurocrine Biosciences, INC. | $183.15 | 2024-2025 | Ingrezza |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $171.31 | 2024-2025 | Briviact |
| Eisai INC. | $164.98 | 2024 | |
| Lundbeck LLC | $102.70 | 2022-2024 | Vyepti |
| Pfizer INC. | $93.58 | 2023-2025 | |
| Inspire Medical Systems, INC. | $86.47 | 2023-2025 | Inspire |
| Sk Life Science, INC. | $78.89 | 2023 | |
| Virtus Pharmaceuticals LLC | $72.58 | 2023-2025 | Levorphanol Tartrate |
| Teva Pharmaceuticals USA, INC. | $56.28 | 2023 | Austedo Xr, Austedo |
| Vertex Pharmaceuticals Incorporated | $48.59 | 2025 | |
| Lilly USA, LLC | $41.03 | 2023 | Emgality, Reyvow |
| Tg Therapeutics, INC. | $33.85 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $31.21 | 2022 | |
| Azurity Pharmaceuticals, INC. | $29.34 | 2023-2024 | Horizant, Horizant |
| Harmony Biosciences LLC | $24.41 | 2023 | Wakix |
| Alexion Pharmaceuticals, INC. | $24.11 | 2023 | Ultomiris |
| Grt US Holding, INC. | $21.85 | 2022 | |
| Avion Pharmaceuticals | $18.86 | 2022 | |
| Medtronic, INC. | $13.91 | 2022 | |
| Uswm, LLC | $13.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ko Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.